glp 1 nausea and diarrhea glp-1 receptor agonist management Side Effects: A Complete Guide to What You Can Expect Exploring the Side Effects of – YouTube

Porter, R

In the SURMOUNT-1 study, a phase 3 clinical trial in obese patients, randomized participants in a 1:1:1:1 ratio to tirzepatide (5, 10, 15 mg) or placebo over 72 weeks, significant weight reductions were observed at 72 weeks: 15.0% for 5 mg, 19.5% for 10 mg, 20.9% for 15 mg, compared to 3.1% for placebo [18]

An association between a lower risk of MACEs and the use of GLP-1 RAs persisted regardless of hypertension, advanced CKD, or insulin/metformin use

2 Although practice now favours earlier use of newer agents shown to have cardiorenal benefits, SUs are still used extensively across the UK, despite causing weight gain and hypoglycaemia

KEY OBSERVATIONS Gimme Care holds active LegitScript certification